- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
- PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
- PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
- PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
- PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
- PaxMedica Announces 1-for-17 Reverse Stock Split
- PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
More ▼
Key statistics
As of last trade, PaxMedica Inc (PXMD:NAQ) traded at 0.6799, 82.77% above the 52 week low of 0.372 set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.705 |
---|---|
High | 0.705 |
Low | 0.6779 |
Bid | 0.6779 |
Offer | 0.70 |
Previous close | 0.692 |
Average volume | 14.30m |
---|---|
Shares outstanding | 7.47m |
Free float | 6.86m |
P/E (TTM) | -- |
Market cap | 5.17m USD |
EPS (TTM) | -15.85 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 15:04 BST.
More ▼